Literature DB >> 10565620

Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).

V Stanghellini1.   

Abstract

BACKGROUND: This paper reports the 3-month prevalence rates of gastrointestinal (GI) symptoms from the Domestic/International Gastroenterology Surveillance Study (DIGEST), and their relationship with demographic factors; namely age, gender and body mass index (BMI).
METHODS: Subjects were recruited from 10 international sites by a total of 5581 face-to-face interviews conducted with randomly selected members of the general population aged 18 years and over (50.6% female; mean age 44 years). The sample was divided according to whether subjects reported 1 or more of 14 GI symptoms, or no GI symptoms. Those with any of 11 upper GI symptoms were then subdivided according to their most bothersome symptom: gastro-oesophageal reflux (GORD)-like symptoms, ulcer-like symptoms or dysmotility-like symptoms. Symptoms were classified as relevant if they were of at least moderate severity and/or occurred at least once a week.
RESULTS: A mean of 46.4% of subjects reported experiencing one or more of the 14 GI symptoms, with 28.1% experiencing upper GI symptoms classified as relevant. Significant differences between the prevalences of relevant symptoms were evident between sampling sites. The estimated prevalence of GORD-like symptoms for the pooled sample was 7.7%. For ulcer-like symptoms, prevalence was 4.1%, and for dysmotility-like symptoms 15.5%. Significant differences were observed in the prevalence rates of symptom groups between countries. Women were significantly more likely than men to experience relevant symptoms, with gender differences also observed in the rates of GORD-like and dysmotility-like symptoms. The proportion of those with relevant symptoms experiencing GORD-like symptoms increased significantly with age; ulcer-like symptoms showed no significant relationship with age; and dysmotility-like symptoms decreased significantly with age. The prevalence of relevant symptoms increased with increasing BMI.
CONCLUSIONS: In conclusion, the DIGEST has provided valuable data on the cross-country prevalence of upper GI symptoms, and their association with biological factors.

Entities:  

Mesh:

Year:  1999        PMID: 10565620     DOI: 10.1080/003655299750025237

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  52 in total

Review 1.  Epidemiology of gastro-oesophageal reflux disease: a systematic review.

Authors:  J Dent; H B El-Serag; M-A Wallander; S Johansson
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

2.  Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.

Authors:  Hatsushi Yamagishi; Tomoyuki Koike; Shuichi Ohara; Toru Horii; Ryousuke Kikuchi; Shigeyuki Kobayashi; Yasuhiko Abe; Katsunori Iijima; Akira Imatani; Kaori Suzuki; Takanori Hishinuma; Junichi Goto; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

3.  Women and functional dyspepsia.

Authors:  Kate Napthali; Natasha Koloski; Marjorie M Walker; Nicholas J Talley
Journal:  Womens Health (Lond)       Date:  2016-02-22

4.  Evaluation of health-related quality of life using EQ-5D in Takamatsu, Japan.

Authors:  Ai Fujikawa; Takeshi Suzue; Fumihiko Jitsunari; Tomohiro Hirao
Journal:  Environ Health Prev Med       Date:  2010-07-07       Impact factor: 3.674

5.  The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.

Authors:  M Vardi; B L Cryer; M Cohen; A Lanas; T J Schnitzer; P Lapuerta; M A Goldsmith; L Laine; G Doros; Y Liu; A I McIntosh; C P Cannon; D L Bhatt
Journal:  Aliment Pharmacol Ther       Date:  2015-05-29       Impact factor: 8.171

6.  Body-mass index and symptoms of gastroesophageal reflux in women.

Authors:  Brian C Jacobson; Samuel C Somers; Charles S Fuchs; Ciarán P Kelly; Carlos A Camargo
Journal:  N Engl J Med       Date:  2006-06-01       Impact factor: 91.245

7.  [Antireflux therapy--more than acid reduction?].

Authors:  T Frieling
Journal:  Internist (Berl)       Date:  2004-12       Impact factor: 0.743

8.  High prevalence of gastroesophageal reflux symptoms in patients with both acute and nonacute cough.

Authors:  Yoshihisa Urita; Toshiyasu Watanabe; Hiroki Ota; Motohide Iwata; Yosuke Sasaki; Tadashi Maeda; Takamasa Ishii; Makie Nanami; Asuka Nakayama; Hirohito Kato; Kazuo Hike; Noriko Hara; Masaki Sanaka; Yoko Nagai; Shuji Watanabe; Kazushige Nakanishi; Hitoshi Nakajima; Motonobu Sugimoto
Journal:  Int J Gen Med       Date:  2008-11-30

9.  Analysis of the gastrointestinal symptoms of uninvestigated dyspepsia and irritable bowel syndrome.

Authors:  Kazutoshi Hori; Takayuki Matsumoto; Hiroto Miwa
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

10.  Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis.

Authors:  Hiroaki Kusunoki; Masayasu Kusaka; Soichiro Kido; Ryo Yamauchi; Yoshinori Fujimura; Yasuyuki Watanabe; Michio Kobori; Hiroto Miwa; Toshihiko Tomita; Yongmin Kin; Kazutoshi Hori; Nobuo Tano; Kenji Sugimoto; Yoshihiro Nakamura; Kazuma Fujimoto; Noriko Oza; Aki Matsunobu; Naofumi Ono; Seisuke Fuyuno; Yoshikazu Kinoshita; Kyoichi Adachi; Mika Yuki; Tomoo Fujisawa; Ken Haruma
Journal:  J Gastroenterol       Date:  2009-03-13       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.